Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
ISSN: 2155-9570
Islam Goda, Hassan Lotfy, Mohammed Sayed, Abdelsalam Abdallah and Mahmoud Abd El-Radi
Assiut University, Egypt
Posters & Accepted Abstracts: J Clin Exp Ophthalmol
This study is to compare the effi cacy and safety of Mitomycin C versus Bevacizumab as adjunctive to trabeculectomy in primary open angle glaucoma. A prospective, comparative, open-label study was conducted at Assiut University Hospital, Assiut, Egypt from January 2014 to November 2016. Th irty eyes from 30 patients with uncontrolled primary open angle glaucoma were enrolled. 15 eyes underwent trabeculectomy with subconjunctival bevacizumab injection (1.25 mg/0.05 mL) and 15 eyes underwent trabeculectomy with MMC (0.02% for 3 minutes). Th e primary outcome measure was IOP while the secondary outcome measures were number of IOP lowering medications and bleb morphologic features (based on the Indiana Bleb Appearance Grading Scale). Follow-up times were six months. Th e mean preoperative IOP in the Bevacizumab group decreased from 29.80�±2.83 mmHg with 2.67�±0.98 anti-glaucoma medications to 14.13�±5.58 mmHg with 1.00�±1.13 anti-glaucoma medications at the last visit (P<0.001 and P<0.001, respectively). Th e mean preoperative IOP in the MMC group decreased from 28.40�±2.06 mm Hg with 2.40�±0.99 anti-glaucoma medications to 12.27�±4.85 mm Hg with 0.87�±1.06 antiglaucoma medications at the fi nal visit (P<0.001 and P<0.001, respectively). Th ere was no statistically signifi cant diff erence in the IOP between the two groups at the last visit (P<0.250). Th e cumulative probabilities of total success at the last follow-up according to Kaplan-Meier analysis were 86.7% and 79.9% in MMC and bevacizumab groups, respectively.